JP2013544892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544892A5 JP2013544892A5 JP2013543331A JP2013543331A JP2013544892A5 JP 2013544892 A5 JP2013544892 A5 JP 2013544892A5 JP 2013543331 A JP2013543331 A JP 2013543331A JP 2013543331 A JP2013543331 A JP 2013543331A JP 2013544892 A5 JP2013544892 A5 JP 2013544892A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (13)
- 薬学的に許容しうる担体をさらに含む、請求項1に記載の組成物。
- 式(1)の前記化合物及び式(2a)又は(2b)の前記化合物が、前記組成物が患者に投与されたとき患者における腫瘍体積の減少において相乗効果を生じる量である、請求項1に記載の組成物。
- 治療有効量の式(1)の化合物又はその薬学的に許容しうる塩を、式(2a)若しくは式(2b)の化合物、又はその薬学的に許容しうる塩と組み合わせて含む、がん患者を処置するための医薬。
- 有効量が、前記患者における腫瘍体積の減少において相乗効果を達成する、請求項4に記載の医薬。
- 有効量が、前記患者における腫瘍静止を達成する、請求項4に記載の医薬。
- 前記がんが、肺非小細胞がん、乳がん、膵臓がん、肝臓がん、前立腺がん、膀胱がん、子宮頸がん、甲状腺がん、結腸直腸がん、肝臓がん、筋がん、血液学的悪性疾患、黒色腫、子宮内膜がん及び膵臓がんからなる群より選択される、請求項4に記載の医薬。
- がんが、結腸直腸がん、子宮内膜がん、血液学的悪性腫瘍、甲状腺がん、乳がん、黒色腫、膵臓がん及び前立腺がんからなる群より選択される、請求項4に記載の医薬。
- 式(2a)の化合物を含む、請求項4に記載の医薬。
- 式(2b)の化合物を含む、請求項4に記載の医薬。
- 治療有効量の、(A)式(1)の化合物、又はその薬学的に許容しうる塩、及び(B)式(2a)若しくは式(2b)の化合物、又はその薬学的に許容しうる塩を含む、がんの処置における使用のための組み合わせ。
- (A)式(1)の化合物、又はその薬学的に許容しうる塩;(B)式(2a)若しくは式(2b)の化合物、又はその薬学的に許容しうる塩;及び(C)使用のための指示書を含んでなるキット。
- がんの処置における使用のための医薬の製造のための、治療有効量の(A)式(1)の化合物、又はその薬学的に許容しうる塩、及び(B)式(2a)若しくは式(2b)の化合物、又はその薬学的に許容しうる塩を含む組み合わせの使用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42146510P | 2010-12-09 | 2010-12-09 | |
US61/421,465 | 2010-12-09 | ||
US201161436258P | 2011-01-26 | 2011-01-26 | |
US61/436,258 | 2011-01-26 | ||
US201161467485P | 2011-03-25 | 2011-03-25 | |
US61/467,485 | 2011-03-25 | ||
FR1159940 | 2011-11-03 | ||
FR1159940 | 2011-11-03 | ||
PCT/US2011/063871 WO2012078832A1 (en) | 2010-12-09 | 2011-12-08 | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013544892A JP2013544892A (ja) | 2013-12-19 |
JP2013544892A5 true JP2013544892A5 (ja) | 2015-01-22 |
Family
ID=45464841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013543331A Abandoned JP2013544892A (ja) | 2010-12-09 | 2011-12-08 | Pi3k阻害剤及びmek阻害剤を含む組成物並びにがんの処置のためのそれらの使用 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20140024653A1 (ja) |
EP (1) | EP2648729A1 (ja) |
JP (1) | JP2013544892A (ja) |
KR (1) | KR20140011311A (ja) |
CN (1) | CN103402518A (ja) |
AR (1) | AR084216A1 (ja) |
AU (1) | AU2011338354A1 (ja) |
BR (1) | BR112013014198A2 (ja) |
CA (1) | CA2820748A1 (ja) |
CL (1) | CL2013001643A1 (ja) |
CR (1) | CR20130246A (ja) |
DO (1) | DOP2013000131A (ja) |
MA (1) | MA34815B1 (ja) |
MX (1) | MX2013006319A (ja) |
NZ (1) | NZ611581A (ja) |
PE (1) | PE20140702A1 (ja) |
RU (1) | RU2013131241A (ja) |
SG (1) | SG190368A1 (ja) |
TW (1) | TW201306837A (ja) |
UY (1) | UY33790A (ja) |
WO (1) | WO2012078832A1 (ja) |
ZA (1) | ZA201303687B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150003786A (ko) * | 2012-04-06 | 2015-01-09 | 사노피 | Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법 |
CN104703655A (zh) * | 2012-10-11 | 2015-06-10 | 默克专利股份公司 | 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 |
ES2945387T3 (es) * | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
WO2016014390A1 (en) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer |
BR112020012388A2 (pt) * | 2017-12-22 | 2020-11-24 | Adienne S.A. | método para a determinação in vitro da potência de um ligante anti-cd26 |
WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
KR20230088451A (ko) * | 2020-10-16 | 2023-06-19 | 메모리얼 슬로안 케터링 캔서 센터 | 암 요법을 위한 페롭토시스의 유도 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/es unknown
- 2011-12-08 TW TW100145212A patent/TW201306837A/zh unknown
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/es not_active Application Discontinuation
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/pt not_active IP Right Cessation
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/es not_active Application Discontinuation
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/ko not_active Application Discontinuation
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/en not_active Withdrawn
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/zh active Pending
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/ja not_active Abandoned
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/en active Application Filing
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/ru not_active Application Discontinuation
- 2011-12-08 MA MA36091A patent/MA34815B1/fr unknown
- 2011-12-08 CA CA2820748A patent/CA2820748A1/en not_active Abandoned
- 2011-12-09 UY UY0001033790A patent/UY33790A/es not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/es unknown
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/es unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013544892A5 (ja) | ||
JP2017518302A5 (ja) | ||
JP2022017295A5 (ja) | ||
JP2016501221A5 (ja) | ||
JP2013509429A5 (ja) | ||
TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
JP2017525730A5 (ja) | ||
JP2016536286A5 (ja) | ||
JP2015536964A5 (ja) | ||
JP2013507415A5 (ja) | ||
JP2014509659A5 (ja) | ||
WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
JP2015503596A5 (ja) | ||
RU2015125307A (ru) | Комбинированная терапия | |
RU2015106524A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf | |
JP2013542247A5 (ja) | ||
JP2010001302A5 (ja) | ||
JP2014512354A5 (ja) | ||
JP2013522326A5 (ja) | ||
GEP201706678B (en) | Method of treating cancer and bone cancer | |
RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
JP2015193630A5 (ja) | ||
JP2014530181A5 (ja) | ||
JP2015511609A5 (ja) | ||
MX2013011532A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). |